Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world data
Authors' conclusion
Weight loss in patients prescribed semaglutide from real-world evidence was strong but attenuated compared with previous clinical trials. Machine-learning analysis of electronic health record data identified factors that warrant further research and consideration when tailoring weight-loss therapy.
Study context
- Population
- Patients prescribed semaglutide in 10 health systems of the Greater Plains Collaborative (PCORnet), March 2017 to April 2022539 observed at 52 weeks
- Participants
- 3,555 patients
- Outcome
- Weight loss (% of initial weight)
Methodological detailsreal-world data, multicentre (10 health systems), machine-learning (gradient-boosting classifier, SHAP)
- Real-world data
- Multicentre (10 health systems)
- Machine-learning (gradient-boosting classifier, SHAP)
Main finding
As reported in the abstract
Weight loss, % of initial weight
Average weight loss, all
4.44%
Average weight loss, male individuals
3.66%
Average weight loss, female individuals
5.08%
Observational data: associations, not effects.
Further findings
Factors associated with weight loss (SHAP)
- History of DM diagnosis associated with less weight loss
- Prediabetes and linaclotide use associated with more pronounced weight loss
Original publication
Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world data. Obesity (Silver Spring). Published 18 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →